Skip to main content
SpringerLink
Log in

Kryoablation des Prostatakarzinoms

Cryoablation of prostate cancer

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Die kontinuierliche technische Entwicklung über mehr als 60 Jahre und daraus resultierende bessere klinische Ergebnisse bei geringerer Nebenwirkungsrate haben die Kryoablation der Prostata zu einer echten Alternative bei der Behandlung des lokalisierten Prostatakarzinoms bei selektionierten Patienten werden lassen.

Thema

Die heutige Form der Kryotherapie hat fast nichts mehr mit der in den 1960er und 1970er Jahren entwickelten und in den 1980er und 1990er Jahren verbesserten Variante gemeinsam. Die heutige minimale Invasivität und hohe Wirksamkeit bei High-risk-Karzinomen zum einen und Versagern anderer therapeutischer Modalitäten zum anderen ergeben das Anwendungsspektrum. Kryoablation ist indiziert bei absoluter oder relativer Kontraindikation zur radikalen Operation.

Schlussfolgerung

In der Salvagesituation bei noch lokalisiertem Prostatakarzinom ist die Kryoablation derzeit Therapie der Wahl. Die Kryotherapie ist auch eine ideale Option zur fokalen Therapie. Nicht zuletzt wurde dieser Stellenwert durch eine Standardisierung der Prozedur, exakte Definition des Ablaufs und strukturierte Trainingsprogramme erreicht.

Abstract

Background

Due to continuous technical developments for more than 60 years followed by better clinical results with minimal side effects, cryoablation of the prostate for localized prostate cancer has evolved as a true alternative therapeutic option for selected patients.

Themata

The current form of cryoablation has almost nothing in common with those established in the 1960s and 1970s, which were further developed in the 1980s and 1990s. Nowadays it is a minimally invasively and highly effective treatment for high-risk carcinomas and failure of other therapeutic modalities.

Conclusion

Thus, cryoablation of the prostate is indicated if there are absolute or relative contraindications for radical surgery. In salvage cases for localized prostate cancer, cryoablation is the therapy of choice. Cryoablation is also an option for focal therapy. Standardization of the procedure, definition of freeze-thaw cycles, and structured training programs have led to this status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Hoffmann NE, Bischof JC (2002) The cryobiology of cryosurgical injury. Urology 60(Suppl 2):40–49

    Article  PubMed  Google Scholar 

  2. Gage AA, Baust J (1998) Mechanisms of tissue injury in cryosurgery. Cryobiology 37:171–186

    Article  CAS  PubMed  Google Scholar 

  3. Tatsutani K, Rubinsky B, Onik G, Dahiya R (1996) Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Urology 48:441–447

    Article  CAS  PubMed  Google Scholar 

  4. Larson T, Robertson D, Corica A, Bostwick D (2000) In vivo interstitial temperature mapping of the human prostate during cryosurgery with correlation to histopathological outcomes. Urology 55:547–552

    Article  CAS  PubMed  Google Scholar 

  5. Patel B, Parsons C, Bidair M, Schmidt J (1996) Cryoablation for carcinoma of the prostate. J Surg Oncol 63:256–264

    Article  CAS  PubMed  Google Scholar 

  6. Moore Y, Sofer P (2001) Successful treatment of locally confined prostate cancer with the seed Net™ system – preliminary multicenter results. Clin Appl Notes 1–7

  7. Cytron S, Paz A, Kravchick S et al (2003) Active rectal wall protection using direct transperitoneal cryo-needles for histologically proven prostate adenocarcinomas. Eur Urol 44:315–321

    Article  PubMed  Google Scholar 

  8. Bahn D, Lee F, Badalament R et al (2002) Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 60(Suppl 2):3–11

    Article  PubMed  Google Scholar 

  9. Donnelly B, Saliken J, Ernst D et al (2002) Prospective trial of cryosurgical ablation of the prostate: fife-year results. Urology 60:645–649

    Article  CAS  PubMed  Google Scholar 

  10. Zisman A, Pantuck A, Cohen J, Belldegrun A (2001) Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17 gauge brachytherapy template-technique and preliminary results. Urology 58:988–993

    Article  CAS  PubMed  Google Scholar 

  11. Long J, Bahn D, Lee F et al (2001) Five-year retrospective multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 57:518–523

    Article  CAS  PubMed  Google Scholar 

  12. Cohen JK (2004) Cryosurgery of the prostate: techniques and indications. Rev Urol 6(Suppl 4):520–526

    Google Scholar 

  13. Katz AE, Rewcastle JC (2003) The current and potential role of cryoablation as a primary therapy for localized prostate cancer. Curr Oncol Rep 5:231–238

    Article  PubMed  Google Scholar 

  14. Lambert EH, Bolte K, Masson P et al (2007) Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 69(6):1117–1120

    Article  PubMed  Google Scholar 

  15. Witzsch U, Dillenburg W, Poulakis V, Becht E (2006) Kryotherapie des lokalisierten Prostatakarzinoms (PCA) mit Technologie der 3. Generation – Erfahrungen nach 4 Jahren. Urologe (Suppl 1):75

  16. Witzsch U, Dillenburg W, Hellwig W et al (2007) Cryoablation of prostate cancer using 17 Gauge cryoneedles technology, 5 year european experience. Eur Urol 6(Suppl 2):201

    Article  Google Scholar 

  17. Witzsch UKF, Greene D, Bjerklund TE (2009) Third generation cryosurgery for prostate cancer – european experience. Eur Urol 8(Suppl 4):362

    Article  Google Scholar 

  18. Cohen J, Miller R, Ahmed S et al (2008) Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 71(3):515–518

    Article  PubMed  Google Scholar 

  19. Prepelica K, Masson P, Benson MC et al (2005) Salvage cryosurgical Ablation of the Proastate (TCAP) for patients failing radiation 10 year experience. AUA 1662

  20. Ahmed S, Lindsay B, Davies J (2004) Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy. Prostate Cancer Pediatric Dis 1–5

  21. Witzsch UKF, Skriapas K, Hieronymi S, Becht E (2009) Salvage cryoablation of prostate cancer using 17 Gauge cryoneedles technology 7 year european experience. Eur Urol Suppl 8(4):361

    Article  Google Scholar 

  22. Hale Z, Miyake M, Palacios DA, Rosser CJ (2013) Focal cryosurgical ablation of the prostate: a single institutes perspective. BMC Urol 13:2

    Article  PubMed Central  PubMed  Google Scholar 

  23. Abreu ALC de, Duke B, Scott L et al (2013) Salvage focal and salvage total cryoablation for locally recurrent prostate cancer after primary radiation therapy. BJU Int 112:298–307

    Article  Google Scholar 

  24. Witzsch U, Hieronymi S, Voss G, Becht E (2011) Salvage cryoablation for prostate cancer using 17 G cryoneedles technology is an local option after radical prostatectomy failure (223). Eur Urol 10(Suppl):92

    Article  Google Scholar 

  25. Witzsch U, Greene D, Borre M, Bjerklund T (2012) Salvage and primary 17 G cryosurgery for prostate cancer – 10 year European experience (21). Eur Urol 11(Suppl):1

    Article  Google Scholar 

  26. Witzsch UKF, Hieronymi S, Dillenburg W, Becht E (2012) Outcome predictor after Cryoablation of prostate cancer using 17 gauge cryoneedles technology is the 3 Month posttherapy PSA level (983) Eur Urol 11(Suppl):1

  27. Levy D, Ross A, El Shafei A et al (2014) Definition of biochemical success following primary whole gland prostate cryoablation. J Urol 192:1380–1384

    Article  CAS  PubMed  Google Scholar 

  28. Katz AE, Prepelica KL, Masson P et al (2005) Salvage cryosurgical ablation of the prostate (TCAP) for patients failing radiation: 10-year experience. J Urol 173:450

    Article  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. U.K.F. Witzsch bis 2013 Trainer für Kryotherapie (Berater Galil Medical). Aktuell Trainer für HIFU EDAP TMS. U.K.F. Witzsch und E. Becht geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Krankenhaus Nordwest GmbH, Stiftung Hospital zum Heiligen Geist, Steinbacher Hohl 2–26, 60488, Frankfurt/Main, Deutschland

    U.K.F. Witzsch & E. Becht

Authors
  1. U.K.F. Witzsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Becht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U.K.F. Witzsch.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Witzsch, U., Becht, E. Kryoablation des Prostatakarzinoms. Urologe 54, 191–201 (2015). https://doi.org/10.1007/s00120-014-3667-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-014-3667-1

Schlüsselwörter

Keywords

Search

Navigation